XEN 45 Gel Stent Implantation in Open Angle Glaucoma: 5-Year Results of a Prospective Study

被引:5
|
作者
Torbey, Julien [1 ]
Paillard, Archibald [1 ]
Rao, Harsha L. [2 ]
Gillman, Kevin [1 ]
Bravetti, Giorgio E. [1 ]
Mermoud, Andre [1 ]
Mansouri, Kaweh [1 ,3 ,4 ]
机构
[1] Glaucoma Res Ctr, Montchoisi Clin, Swiss Visio Network, Lausanne, Switzerland
[2] Narayana Nethralaya, Hulimavu, Bangalore, India
[3] Univ Colorado, Sch Med, Dept Ophthalmol, Denver, CO USA
[4] Montchoisi Clin, Swiss Visio Glaucoma Res Ctr, Ave Servan 38, CH-1006 Lausanne, Switzerland
关键词
glaucoma; microinvasive glaucoma surgery (MIGS); XEN 45 gel stent; surgery; open angle; anterior segment; INTRAOCULAR-PRESSURE; PHACOEMULSIFICATION; SURGERY;
D O I
10.1097/IJG.0000000000002302
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Pr & eacute;cis: XEN 45 Gel Stent is safe and effective for 3 years. The study results provide useful insight into the outcome of XEN 45 Gel Stent surgery over 5 years in daily clinical practice.Purpose: To evaluate 5-year outcomes of XEN 45 gel stent implantation (XEN) in patients with open angle glaucoma.Methods: This is a prospective, single-center, interventional study. XEN implantation either alone (XEN) or combined with phacoemulsification (Phaco + XEN) was performed on 170 consecutive eyes (126 patients) with uncontrolled intraocular pressure (IOP) or disease progression despite medical treatment. "Complete" surgical success at 60 months was defined as unmedicated IOP <= 15 mm Hg and a relative IOP reduction >= 20% from medicated baseline, while "qualified" success allowed fewer ocular hypotensive medications than at baseline. Other definitions of success with various IOP targets were also analyzed. Secondary outcomes included mean IOP and IOP-lowering medication changes and rates of reoperations.Results: Mean age was 78.1 +/- 9.2 years, and 70.3% were female. Mean medicated IOP decreased from 19.8 +/- 7.7 mm Hg [19.6 +/- 7.1 (XEN) vs. 19.8 +/- 7.0 mm Hg (Phaco+XEN)] at baseline to 12.6 +/- 3.1 mm Hg [12.5 +/- 3.1 (XEN) vs. 12.6 +/- 3.1 (Phaco+XEN)] at 5 years (-37.0%; P < 0.001). Medications decreased from 2.0 +/- 1.3 [2.0 +/- 1.3 (XEN) vs. 2.0 +/- 1.3 (Phaco+XEN)] to 0.8 +/- 1.1 [0.8 +/- 1.1 (XEN) vs. 0.8 +/- 1.1 (Phaco + XEN)] (-60%; P<0.001). Needling was performed in 84 eyes (49%), and 19.4% underwent a secondary surgical intervention. Complete success at 3 years was a strong predictor of success at 5 years (odds ratio: 3.06, P<0.01), while needling was associated with higher rates of failure (odds ratio: 3.6, P<0.01).Conclusions: At 5 years, XEN gel stent implantation was a safe procedure and achieved clinically meaningful IOP and medication reduction. Success at 3 years is a predictor of success at 5 years. Needling correlates with higher failure rates.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 50 条
  • [1] XEN45 Gel Stent implantation in eyes with primary open angle glaucoma: A study from a single hospital in Taiwan
    Chao, Yu-Jang
    Ko, Yu-Chieh
    Chen, Mei-Ju
    Lo, Kang-Jung
    Chang, Yu-Fan
    Liu, Catherine Jui-Ling
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (01) : 108 - 113
  • [2] Double implantation of Xen 45 gel stent in primary open-angle glaucoma: a pilot study
    Grosso, Andrea
    Ceruti, Piero
    Garlasco, Jacopo
    Frohlich, Jacqueline
    Orione, Matteo
    Gugleta, Konstantin
    Fioretto, Mauro
    Calzetti, Giacomo
    INTERNATIONAL OPHTHALMOLOGY, 2024, 44 (01)
  • [3] Outcomes of Deep Sclerectomy following Failed XEN Gel Stent Implantation in Open-Angle Glaucoma: A Prospective Study
    Bravetti, Giorgio Enrico
    Gillmann, Kevin
    Rao, Harsha L.
    Mermoud, Andre
    Mansouri, Kaweh
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [4] XEN(R)Gel Stent compared to PRESERFLO™ MicroShunt implantation for primary open-angle glaucoma: two-year results
    Scheres, Lotte M. J.
    Kujovic-Aleksov, Stefani
    Ramdas, Wishal D.
    de Crom, Ronald M. P. C.
    Roelofs, Lianne C. G.
    Berendschot, Tos T. J. M.
    Webers, Carroll A. B.
    Beckers, Henny J. M.
    ACTA OPHTHALMOLOGICA, 2021, 99 (03) : E433 - E440
  • [5] Results of XEN45 Gel Stent Implantation in the Treatment of Primary Open-Angle Glaucoma Using 5, 10 or 20 μg Mitomycin C: A Pilot Study
    Reichel, Felix F.
    Guggenberger, Vanessa
    Faber, Hanna
    Neubauer, Jonas
    Voykov, Bogomil
    JOURNAL OF OPHTHALMOLOGY, 2024, 2024
  • [6] Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry
    Arnould, Louis
    Balsat, Elise
    Hashimoto, Yohei
    White, Andrew
    Kong, George
    Dunn, Hamish
    Fan, Leo
    Gabrielle, Pierre-Henry
    Bron, Alain M.
    Creuzot-Garcher, Catherine P.
    Lawlor, Mitchell
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2024,
  • [7] Three-year clinical outcome of XEN45 Gel Stent implantation versus trabeculectomy in patients with open angle glaucoma
    Rauchegger, Teresa
    Krause, Sarah-Maria
    Nowosielski, Yvonne
    Huber, Anna Lena
    Willeit, Peter
    Schmid, Eduard
    Teuchner, Barbara
    EYE, 2024, 38 (10) : 1908 - 1916
  • [8] Long-Term Effectiveness of XEN 45 Gel-Stent in Open-Angle Glaucoma Patients
    Marcos-Parra, Maria Teresa
    Salinas-Lopez, Javier Alejandro
    Mateos-Marcos, Carlos
    Moreno-Castro, Lucia
    Mendoza-Moreira, Angi Lizbeth
    Perez-Santonja, Juan J.
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 1223 - 1232
  • [9] XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature
    Buffault, J.
    Baudouin, C.
    Labbe, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2019, 42 (02): : E37 - E46
  • [10] Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma
    Rauchegger, Teresa
    Angermann, Reinhard
    Willeit, Peter
    Schmid, Eduard
    Teuchner, Barbara
    ACTA OPHTHALMOLOGICA, 2021, 99 (04) : 369 - 375